szeged, sept. 28th 2007 1 inserm french national institute of health and medical research created in...
Post on 25-Dec-2015
213 Views
Preview:
TRANSCRIPT
1Szeged, Sept. 28th 2007
InsermInsermFrench National Institute of Health
andMedical Research
•Created in 1964 from the National Institute of Hygiene and Hospital Research
•Working through the Ministries for Research and Health
2Szeged, Sept. 28th 2007
Inserm : key figures
Budget 2007 : 700 M€Total staff: 13 000
(2 500 physicians) of which 4900 Inserm employees: 2100 scientists and 2800
technical staff (62% of total budget dedicated to salaries)
335 Inserm laboratories25 research centers
374 French and foreign firms are partners of Inserm
An active patent portfolio of 572 families
41 Clinical Investigation Centers (CIC)
56 start-up companies based on Inserm technology
3Szeged, Sept. 28th 2007
What is Inserm ?
The French performing research organisation entirely dedicated to Biomedical & Clinical research and Public Health
All fields of research are covered in these domains
90% of the 335 research units are located in University hospitals Research units with 8 years mandate with mid-term (4 year)
evaluation. Stringent evaluation
Investigator- driven projects - AVENIR programme
Close collaboration with French Funding agencies (ANR, INCa ANRS), Sanitary agencies (InVS, AFSSAPS), Charities (AFM, …) and industrial partners.
5Szeged, Sept. 28th 2007
OrganizationOrganization Bottom-up initiatives: selection based on Bottom-up initiatives: selection based on
qualityquality and and innovationinnovation
Networks focused on major public health Networks focused on major public health issues: “National Research Programs”:issues: “National Research Programs”:- Diabetes, Cardiovascular, Hepato-Gastro- Diabetes, Cardiovascular, Hepato-Gastro-
EnterologyEnterology- Bone and joint diseases, endocrinology and Bone and joint diseases, endocrinology and
reproduction etc…. reproduction etc….
6Szeged, Sept. 28th 2007
Bone and Joint Diseases
2.2%
Diabetes2.6%
Hepatitis 3.1%
Genetic diseases
10.5%
16.8%Cancer
Cardiovascular diseases
9.1%
17.1%Immunology
of which 9.3%for neurologic disorders
20.6%
Neurosciences
Infectious diseasesand microbiology
(without Aids and Hepatitis)
8.3%
Public health7.5%
Handicap5.1%
Nutrition4.8% AIDS
3.7%
Research laboratories being often involved in more than one domain, the overall distribution is over 100 %
7Szeged, Sept. 28th 2007
Research organizations CNRS, CEA, Inra, Inria, IRD, Pasteur Institute,
Curie Institute
Scientific & medical societies, Patients
associations, Foundation, Charities
Universities Industry
Hospitals
National research & Public health
agencies
International scientific
community
8Szeged, Sept. 28th 2007
Inserm : creation of research centers
Objectives and main characteristics:• Critical mass (100 to 300 staffs),• Mutualisation and Integration• International visibility, Attractiveness
Assessment criteria:• Scientific excellence• Quality of the management :
Governing structure, mutualised administration & managementTechnology transfert and research outcomes
Sharing of technical facitiliesCoordination of scientific events and programmesImplementation of research training programmesInternational scientific council for evaluation of scientific strategy (turn-over of scientific teams : mobility, hosting new scientists or teams,…)
9Szeged, Sept. 28th 2007
25 Research Centers in 2007
Some exemples: 1- Paris 6, Pluri-thematic2- Paris 6, Neurophysiology4- Paris 5, Pluri-thematic5- Créteil, Pluri-thematic6- Lilles, Pluri-thematic7- Dijon, Cancer/Nutrition8- Bordeaux, Neurophysiology9- Grenoble, Neurophysiology10- Grenoble, Cancer11- Toulouse, Pluri-thematic
10Szeged, Sept. 28th 2007
Inserm Unit 5967 departments
550 staffs Strasbourg
3 Avenir programs
Facilities- Cellular imaging- DNA microarray platform- Monoclonal Antibody- Structural biology- Bio-informatic- Protéomics
Thematics- Molecular pathology- Developmental and physiological gentics - Fonctional genomics- Cellular biologie and signal transduction- Molecular neurobiology
Partners- Inserm - Louis Pasteur University- CNRS
Technology transfer- > 20 contrats with industries- Public-private Partnerships
Director : D.Moras
www-igbmc.u-strasbg.fr
11Szeged, Sept. 28th 2007
Facilities- Proteomics- Biotherapy- Cytometry - Cellular imaging - Animal imaging
Centre de recherche Jean-Pierre AubertJPARC
Director : Pierre Formstecher
Thematics- Neurosciences- Cellular différenciation and cancer
Partners- Lille 2 University- Lille University Hospital - Inserm
Inserm Unit 8375 teams
150 staffs Lille
Technology transfer- Public-private Partnerships
www.crjpa.lille.inserm.fr
12Szeged, Sept. 28th 2007
Institut du Fer à MoulinIFM
Director : Jean-Antoine Girault
Facilities- Animals - Cellular imaging- Quantitative PCR- Cytometry- Peptide synthesis- Proteomics
Technology transfer- Public-private Partnerships
ThematicsSignalling mechanisms involved in the nervous system developpement
Partners- Université Paris 6- Paris University hospital- Inserm
Inserm Unit 83919 teams99 staffs
Paris1 Avenir program
13Szeged, Sept. 28th 2007
Evolution of Research Units and Research centers at Inserm (from 2001 to 2007)
14Szeged, Sept. 28th 2007
Research infrastructures
• National Genomic Research Consortium: CNRG National Sequencing Center National Genotyping Center Regional Genopoles Core Facilities • Biosafety-level 4 laboratory
• Local and regional technological plateforms
• Clinical Research Infrastructures
15Szeged, Sept. 28th 2007
Functional exploratory platform/animals
National Biological resources :
11
13
Animal experimentations
Transcriptomics
Proteomics
Bioinformatic
in vivo imaging
Structural biology
Cellular imaging
Sequencing
Human biological resources
Electronic microscopy
Lipidomics
Vegetal experimentations
Chemistry
Bacterial
2
9
6
4
5
4
8
2
1
1
1
1
6
Lille
Rouen
Caen
Paris
Reims
Nancy
StrasbourgRennes
ToursOrléans
DijonNantes
Lyon
Bordeaux
GrenobleClermont-Ferrand
Poitiers
NiceToulouse
MarseilleMontpellier
1 1
2 1 1
1 1
1
2
1 11 1
1 1
1 1
1 1
1 1 1
1
1 1
1
1
1
1
1
6 4
1 4 1
1 1
1
1
1
1
1
Rousset
1
1 1
1 1
1
1
1
1
1
11
1
1
1
1
1
1
1
Research platforms
16Szeged, Sept. 28th 2007
Main Inserm’s priorities
1. « Researchers » : Careers, Training & Mobility
2. To focus Inserm on its main mission: support both basic and clinical research; develop translational research with a multidisciplinary approach
3. To establish Inserm in a European and International context
4. To develop public/private partnerships
18Szeged, Sept. 28th 2007
Career tracks at Inserm
• Junior, temporary contract (5 years with a 3-year intermediate evaluation), high level (research director) contracts
Avenir programEuropean programs: EURYI, ERC
• Permanent positions for senior scientists
19Szeged, Sept. 28th 2007
AVENIR Programme
• Eligibility: Young scientists with permanent or temporary position, clinicians
• Aim: To strengthen the status of young scientists; to recognize, evaluate and continuously promote scientific qualities
• A yearly budget of 200K euros for 5 years
• Minimum lab space of 50 m2
• Running costs
• Salaries, human resources (Post-doc, engineers, technicians)
20Szeged, Sept. 28th 2007
Interface contracts : General principles
• Based on :a permanent position + temporary, 3-5 year contracts
• To reinforce interactions with partners and mobility
- Hospitals: clinical research, medical issues- Health agencies: health policy issues- Universities: teaching, making scientific
information available to the society
• Industry: technological transfer and valorisation
• European partners / European mobility (a new scheme of the Marie Curie actions - PEOPLE programme ?)
21Szeged, Sept. 28th 2007
Interface contracts for Inserm scientists :Tenure position + 3-5 year contracts: " 2/3 – 1/3 "
Tenuredscientists
Hospital
Internationalinstitutions
Sanitary Agencies
« Internal » Inserm
UniversityIndustry
22Szeged, Sept. 28th 2007
Interface Contract grants for MDs
• Reinforce research activities of clinicians and university research assistants and professors
• 3-5 year contracts for clinicians : assistant professors and professors, university employees
• Grant paid by Inserm to hospitals and universities to be used for : - clinical and teaching activities: temporary positions - financing research activities
23Szeged, Sept. 28th 2007
The School of InsermThe School of Inserm
A 3-year Theoretical and Practical Education which leads to a Master’s
• First year of Inserm School - Second year of Medical School :
Special School Intensive Training Session in February
June: Competitive Exam
• Second year of Inserm School - Third year of Medical School
6 month full time Research Clerkship in an Inserm Research Laboratory
• Third year of Inserm School - Interruption of Medical School : Clerkship in a Research Laboratory and educational program for the Master Degree
25Szeged, Sept. 28th 2007
BasicResearch
Preclinical studies : Proof of concept
Inserm Inserm
[CRC]
Inserm
Phases IIb-III
Phase IVCohorts
Clinical trialsClinical trials
Proof of conceptPhases I-IIaBiotherapy
26Szeged, Sept. 28th 2007
Inserm, as a major actor of the Clinical Research in France and in Europe
• To set-up an efficient Translational research towards the benefits of patients
• To develop dedicated performing Research Infrastructures : ECRIN, GMP facilities platforms (innovative biomedicines), BRCs, (Roadmap ESFRI)
• To sponsor clinical studies and innovative therapeutic clinical trials
• To ensure appropriate training of Physicians to Research skills and vice-versa : School of Inserm
• To built a continuum from Basic research to Clinical Research
27Szeged, Sept. 28th 2007
Clinical research infrastructures
2006 2001 2002 2003 2004 2005
Clinical research centers 41 17 21 28 31 41
Tissues Banks 47 16 30 47 47 47
Cohorts 118 131 135 142 147 147
Registries 35 17 29 29 31 35
Networks 22 9 22 22 22 22
28Szeged, Sept. 28th 2007
41 Clinical Investigation Centres
• CIC
• Epidemiology studies
• Biotherapy
Access to patientsSupport to investigators
29Szeged, Sept. 28th 2007
FranceInserm
Spain SCReN
SwedenSweCRIN
GermanyKKS
DenmarkDCRIN
ItalyIRFMN & CIRM
HungaryHECRIN
UKUKCRN
Ireland ICRIN
EFGCP
National networks of Clinical Research Centres / Clinical Trial Units
AustriaATCRIN
SwitzerlandSCRN
EORTC
FinlandFinnCRIN
European Clinical Research Infrastructures Network, co-ordinated by INSERM:Pan-Europeaninfrastructure providing services to the preparation and the conduct of multinational clinical studies, with GMP facilities for biotherapy
30Szeged, Sept. 28th 2007
Biological Resources Centres
a networking action at both National and European Levels
31Szeged, Sept. 28th 2007
• Science Case: A European network to coordinate European Scientific programs
and policies Clinical data and follow-up of patients and Healthy volunteers Innovative targets, biomarkers, clinical studies Technology transfer, dissemination of knowledge, valorisation
• Technical case: Repositories for qualified biological samples (DNA, RNA, proteins,
…), coupled to clinical data. Providers/distributors of samples within scientific project objectives Development of QA standards for European BRCs To store samples for the future (heritage) Distributed facilities / centralised database
Network of Biological Resources Facilities Cohorts of Patients
32Szeged, Sept. 28th 2007
The necessity of a European network :
To co-ordinate European scientific programs and policies : 7th PCRD
To develop and harmonize assurance-quality standards for European BRCs : exchanges of authenticated biological materials.
Valorisation of knowledge
Attractiveness of public research and development of innovative SMEs.
European Biological Resources network (BBMRI)
33Szeged, Sept. 28th 2007
Platforms for GMP production
State of the art :
Platforms for production of therapeutic vectors : Nantes (Atlantic biothérapies), Généthon, etc.
Platforms for production of bio-medicines : LFB, Genopole Ile-de-France, Vivalis, Lipidomix, etc.
Platforms for production of therapeutic virus : Heidelberg
Perspectives : availability of GMP products
Partnership with Inserm-Transfert Costs sharing European dimension : ESFRI / IMI
34Szeged, Sept. 28th 2007
EU approach for of GMP Facilities
• Needs : to develop innovative “non-commercial” clinical trials - Lack of specific financial support
• Science Case: Reinforcing clinical research and translation of basic research to
therapy Production and evaluation of innovative therapeutic and
diagnostic agents : biomarkers and biotherapy / regenerative medicine : cell therapy, gene therapy, tissue engineering
• Technical case: Production of new therapeutic/diagnostic agents from
biotechnologies Products for Cell and Gene therapy Good Manufacturing Practices (GMO dissemination regulation), in
line with national legislation, able to cooperate across the borders Direct links with Clinical Research Centres (CRC - ECRIN)
35Szeged, Sept. 28th 2007
IMI : Innovative Medicines for Europe
European Joint Technology Initiative (JTI) to develop new therapeutic drugs in a faster and safer way.
Inserm is the French representative in the Member states contact Group of IMI
36Szeged, Sept. 28th 2007
Competitivity Clusters
Atlantic Biothérapies
Cancer Bio Santé
Prod’Innov
Lyonbiopôle Virology
Innovations thérapeutiques
Nutrition Santé Longévité
Medicen
Orpheme
Nutrition
International
National
Emergent
Imaging, Cancer, Biotehrapy, Neurosciences
Cancer Bio SantéRéunion
Qualitropic
67 created clusters 7 involving Inserm units
38Szeged, Sept. 28th 2007
Inserm’s priorities in Europe
1. « Researchers » : attractive careers, training, mobility
2. “European” Research Laboratories: European Associated Laboratories, Joint Unit abroad
3. Research Infrastructures for biomedical research (ECRIN, Biobanks, EATRIS) and Translational research based on Public-Private Partnership (IMI - European Joint Technology Initiative)
4. FP7 and other European programmes of interest
5. EU Prospectives (ESF-EMRC, EUROHORCS,etc.)=> Green paper on new perspectives of ERA
39Szeged, Sept. 28th 2007
Multilateral cooperations’ actions
Inserm in FP6Inserm in FP6
• around 150 EU research projects• 224 participating research teams• 26 in coordination
Inserm in FP7Inserm in FP7
First call of the Health priority : Total of 152 selected projects, out of which7 coordinated by Inserm
(preliminary data)
40Szeged, Sept. 28th 2007
Bilateral cooperations’ actions
Researchers' mobility (short-medium term, Interface Contract grants)
European research networks at the bilateral level and within the EU programmes
European Associated laboratories
Joint Research unit abroad
41Szeged, Sept. 28th 2007
Bilateral cooperations’ tools:Associated Laboratories and Inserm’s Units abroad
Scientifically driven
8 years mandate with mid-term evaluation
Synergies: competencies and facility access
Co-funded by Inserm and Associated partner
Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)
Institutional “label”
Leverage effect for additional funding
42Szeged, Sept. 28th 2007
BrusselsHeidelberg
Glasgow
Rome
Milan
Prague
Dundee
Barcelona
Porto
European Associated Laboratories (LEA)
Toulouse : D. Langin U586 / Prague : V. Stich (Univ. Charles)
Lille : M. Capron U547 / Brussels : M. Goldman (IMI)
Toulouse : AC Prats U589 / Dundee : JC Bourdon (Univ. Dundee)
Bordeaux: A. Bikfalvi E 113 / Milan: L. Bello (Univ. Degli Stuli)
Nice: G. Meneguzzi U 634 / Rome: G. Zambruno (IDI-IRCCS)
Villejuif: D. Samuel U 785 / Rome: M. Levrero (Univ. La Sapienza)
Montpellier: K. Ritchie U 888 / London: G. Thornicroft (King’s College of London)
Strasbourg: T. Baumert U 748 / Freiburg: H. Blum (Univ. of Freiburg)
Villejuif: T. Moreau U 780/ Barcelona: J. Antό (PRBB, IMIM-CREAL)
Bordeaux: L. Bordenave U 577 / Porto: M. Barbosa (IBMC, INEB)
London
Freiburg
Joint Research Unit in Europe:
Université de Glasgow / C. Doerig
U609
DKFZ / J. Rommelaere U701
43Szeged, Sept. 28th 2007
Montreal
Pittsburgh
Rio de Janeiro
INSERM UnitAssociated LaboratoryIn preparation
Irvine
Montreal
Shanghai
Tokyo
Kyoto
SeoulNew York
NanjingDallas
BeijingHaïfa
Doha
Los Angeles
Buenos Aires
Laval
WuhanRabat
Guangzhou
Singapour
44Szeged, Sept. 28th 2007
International Cooperation Contracts (up to 4 years) Salary paid by “home” institution + additional salary
paid by “host” institution Reciprocal, bi-directional (Imperial College London,
CNR,…)=> Marie Curie « Co-fund » Programme (FP7)
Joint Post-doctoral training contracts
2 phases, commitment for a contractual recruitment when they return, bidirectional call for applications
Prospectives towards Internationalisation of School of Inserm
European Mobility of Researchers« Towards a European Career Track »
45Szeged, Sept. 28th 2007
Joint post-doctoral career track
• 3-year post-doctoral positions in host institutions: Joint selection with Inserm
Joint calls under preparation with European
institutions (ICL, Univ. Dundee, Porto…)
• Evaluation at the end of post-doctoral fellowship
• Junior, 5-year Inserm contract
• Tenure: Inserm, CNRS, University, industry etc ..
46Szeged, Sept. 28th 2007
Cooperations between Inserm and Cooperations between Inserm and Hungarian PartnersHungarian Partners
46
148 joint publications Inserm – Hungarian partners since 2000
Main Partner Institutions : Institutes of the Hungarian Academy of Sciences (BRC Szeged), Semmelweis University Budapest, University of Debrecen
Main thematic areas : Neurosciences, Cardiovascular diseases, Molecular and Cell Biology, Biochemistry etc.
6 Hungarian Researchers and Fellows within Inserm's research units in 2006
18 FP6 projects involving Inserm and Hungarian partners(6 NoEs - 10 IPs - 2 STREP)
Further FP7 collaborations (IMI, ECRIN, BRCs…)
47Szeged, Sept. 28th 2007
TransfertTransfert
• Inserm’s private subsidiary• Created in 2001, funded up to € 4,5 million• 60 people with scientific/industrial background
Missions:• Drive value creation from Inserm research• Allow an efficient partnering with the Industry• Ensure a fair economic return towards Inserm• Contribute to economic development
48Szeged, Sept. 28th 2007
Development of services covering the whole technology transfer process :
• Detection of inventions / “coaching”• Protection of inventions & follow up / intellectual property management• Pre-technology transfer / Applied and Translational Research• Technology Transfer, collaborative and R&D agreements• Preclinical Development / Proof of Concept development• Industrial Partnerships / Clinical trials development• International and European projects management• Biotech start up coaching and funding (pre seed fund Inserm Transfert Initiative)• Legal and financial expertise
Proximity between both scientific and industrial communitiesfor a best partnership development
Integrated Technology Transfer Skills“From the bench to the partnering and the license”
InsermResearch
Intellectual Property License
Biotech start-up
Detection of Inventions
TransfertTransfert
49Szeged, Sept. 28th 2007
Contacts :Inserm’s web site : www.inserm.fr/en/inserm
Department of French Regional and European Strategic Policies
• Anne Bisagni, Director : anne.bisagni@tolbiac.inserm.fr
• Philippe Arhets, Deputy Director : philippe.arhets@tolbiac.inserm.fr
• Cécile Bergouignan, Bilateral cooperation :
cecile.bergouignan@tolbiac.inserm.fr
Human Resources : Researchers task force
• Anne-Marie Laffaye, School of Inserm, Avenir :
anne-marie.laffaye@tolbiac.inserm.fr
• Richard Salives, Marie Curie Programme :
richard.salives@tolbiac.inserm.fr
top related